For Biogen Idec's second quarter, multiple sclerosis star Tecfidera blew analysts' estimates out of the water, as it's been wont to do. But it wasn't Tecfidera alone that helped the Massachusetts biotech trounce sales estimates by about $250 million.
What's better than beating sales estimates with a new drug? Blowing those estimates out of the water. Biogen Idec can celebrate that today, thanks to $700 million in quarterly Tecfidera sales.
Alkermes has its sights set on Biogen Idec's blockbuster multiple sclerosis treatment, advancing a me-better candidate of its own into Phase I study.
Biogen Idec's multiple sclerosis pill Tecfidera has been steamrolling since it hit the U.S. market last April. And now, it's poised to pad global sales with a victory in the U.K., whose cost watchdog has given it the OK in final guidance after flip-flopping on a February decision not to endorse the drug.
Back in April, Biogen Idec stirred up the hemophilia B market by pricing its long-acting newcomer Alprolix on par with older meds. Now, it's doing the same with April approval Eloctate, another long-lasting drug--but in a hemophilia A market where the stakes are much, much higher.
Biogen's multiple sclerosis drug Tecfidera has racked up $1.38 billion in sales since its launch last April, and now the company can claim another feather in the drug's cap: It has the best safety profile of any of its peers. That's the conclusion of a new report out from AdverseEvents, which analyzes side-effects data filed with the FDA.
New drug approvals may have dropped from 2012's high of 43 to 35 last year. But that doesn't mean 2013's crop lacks superstars.
Biogen Idec and AbbVie announced Monday morning that their once-monthly multiple sclerosis drug daclizumab has cleared key hurdles in a Phase III study, setting the stage for a marketing pitch to regulatory authorities.
With Friday's FDA nod for Eloctate, Biogen Idec won approval for its second long-acting hemophilia treatment this year. But while both will shake up their respective markets, this one--a hemophilia A treatment--will be where the money is.
Just a couple of months after scoring a groundbreaking approval for its new hemophilia B drug, Biogen Idec has scored another FDA OK for Eloctate, a hemophilia A drug targeting a much broader blockbuster market.